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Reporting of Multi-Arm Parallel-Group Randomized Trials
Extension of the CONSORT 2010 Statement
Edmund Juszczak, MSc; Douglas G. Altman, DSc; Sally Hopewell, DPhil; Kenneth Schulz, PhD
IMPORTANCE The quality of reporting of randomized clinical trials is suboptimal. In an era in
which the need for greater research transparency is paramount, inadequate reporting hinders
assessment of the reliability and validity of trial findings. The Consolidated Standards of
Reporting Trials (CONSORT) 2010 Statement was developed to improve the reporting of
randomized clinical trials, but the primary focus was on parallel-group trials with 2 groups.
Multi-arm trials that use a parallel-group design (comparing treatments by concurrently
randomizing participants to one of the treatment groups, usually with equal probability) but
have 3 or more groups are relatively common. The quality of reporting of multi-arm trials
varies substantially, making judgments and interpretation difficult. While the majority of the
elements of the CONSORT 2010 Statement apply equally to multi-arm trials, some elements
need adaptation, and, in some cases, additional issues need to be clarified.
OBJECTIVE To present an extension to the CONSORT 2010 Statement for reporting multi-arm
trials to facilitate the reporting of such trials.
DESIGN A guideline writing group, which included all authors, formed following the
CONSORT group meeting in 2014. The authors met in person and by teleconference
bimonthly between 2014 and 2018 to develop and revise the checklist and the accompanying
text, with additional discussions by email. A draft manuscript was circulated to the wider
CONSORT group of 36 individuals, plus 5 other selected individuals known for their specialist
knowledge in clinical trials, for review. Extensive feedback was received from 14 individuals
and, after detailed consideration of their comments, a final revised version of the extension
was prepared.
FINDINGS This CONSORT extension for multi-arm trials expands on 10 items of the
CONSORT 2010 checklist and provides examples of good reporting and a rationale for the
importance of each extension item. Key recommendations are that multi-arm trials should be
identified as such and require clear objectives and hypotheses referring to all of the
treatment groups. Primary treatment comparisons should be identified and authors should
report the planned and unplanned comparisons resulting from multiple groups completely
and transparently. If statistical adjustments for multiplicity are applied, the rationale and
method used should be described.
CONCLUSIONS AND RELEVANCE This extension of the CONSORT 2010 Statement provides
specific guidance for the reporting of multi-arm parallel-group randomized clinical trials and
should help provide greater transparency and accuracy in the reporting of such trials.
JAMA. 2019;321(16):1610-1620. doi:10.1001/jama.2019.3087
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M ulti-arm randomized clinical trials have several formsbut are typically a combination of elements, includingmultiple active interventions, combinations of active
interventions, different doses (or regimens) of an intervention, a
placebo, and no active intervention, or treatment as usual. These
elements can be combined in various ways resulting in numerous
possible trial structures. For example, in a trial with 3 treatment
groups, A1 vs A2 vs A3 could represent an evaluation of different
doses of the same active intervention. Alternatively, a trial of A1
vs B1 vs C1 could represent an evaluation of 2 different active
interventions and a placebo. Moreover, a study comparing A1 vs
A2 vs B1 could represent an evaluation of 2 different doses of an
active intervention vs another active intervention.
Evaluating more than 1 new intervention concurrently
increases the chances of finding an effective intervention.1 The
corresponding increase of efficiency in using a multi-arm (ie,
multi-group) design, compared with performing sequential 2-arm
(ie, 2 groups) trials, should result in lower cost due to better use
of resources. In most cases, sharing a control arm reduces the
sample size relative to performing separate 2-arm trials.2 Offering
participants a higher probability of being allocated to a new inter-
vention may result in a greater proportion of eligible individuals
enrolling. Some multi-arm trials in oncology have recruited more
quickly than comparable 2-arm trials.1 The argument against
multi-arm trials primarily involves statistical power because pub-
lished trials can have inadequate sample sizes.3 Given a finite
number of potential participants, adding additional treatment
groups can further dilute already insufficient power.
Multi-arm trials are relatively common. A detailed review of
all randomized trials indexed in PubMed published in 1 month in
2012 showed that 1062 of 1351 (79%) were parallel-group trials4;
of these 1062 trials, 149 (14%) had 3 groups and 76 (7%) had 4 or
more groups.
In this Special Communication, an extension of the Consoli-
dated Standards of Reporting Trials (CONSORT) checklist for
the reporting of multi-arm trials is presented, based on the
CONSORT 2010 Statement.5,6 Illustrative examples and explana-
tions for items that differ from the main CONSORT checklist
are included. A multi-arm trial is defined as a randomized clinical
trial that uses a parallel-group design but has 3 or more groups.
For describing the intervention groups in clinical trials, the terms
“arms” or “groups” may be used interchangeably, although the
term “multi-arm” is used for these reporting guidelines. Other
multi-arm or multi-group designs, such as factorial, multi-arm




The guideline writing group (which included E.J., D.G.A., S.H., and
K.S.) formed following a meeting of the CONSORT Group in 2014.
The Oxford-based authors met in person with the United States–
based author by teleconference bimonthly, and on multiple addi-
tional occasions, between 2014 and 2018 to develop and revise
the checklist and the accompanying examples and text, with
additional discussions by email.
Search Strategy
To identify articles relevant to the methodology of multi-arm ran-
domized trials, a search of PubMed was conducted using the terms
“multiarm,” “multi-arm,” “multiple arm,” “multiple treatment,” and
“multiplicity” combined with the Publication Type term “random-
ized controlled trial” as a topic, which identified 247 potential ar-
ticles. One author (S.H.) assessed the titles and abstracts for rel-
evance or potential relevance to this CONSORT extension. The search
was supplemented with relevant articles from the personal collec-
tions of the authors and by searching the table of contents of books
relevant to the methodology of clinical trials for information spe-
cific to the conduct and reporting of multi-arm trials.
Review and Refinement
No formal Delphi process was used in developing this CONSORT
extension checklist. The draft manuscript was circulated in April
2017 for review to the wider CONSORT Group, which included 36
individuals, plus 5 selected individuals known for their specialist
knowledge in clinical trials. Feedback was received from 14 indi-
viduals and, after detailed consideration of their comments, a final
revised version of the extension checklist and accompanying expla-
nation was prepared.
Results
Checklist Items and Explanation
The Table shows the modified checklist for the reporting of multi-
arm parallel-group randomized trials; some items are extended to
cover the reporting requirements related to the multi-arm design,
acknowledging the added complexity imposed by this design. Items
that required an extension from the CONSORT 2010 Statement are
explained, with illustrative examples of good reporting. For items
not mentioned, the advice is the same as for 2-group, parallel ran-
domized trials.
Because all examples have been taken from published articles,
it is inevitable that several do not display all of the desirable ele-
ments of good reporting. When this is the case, or when there might
be ambiguity, the specific aspects of good reporting that are ad-
dressed are identified. In some examples, text has been added in
brackets to explain the context. The CONSORT 2010 checklist for
Key Points
Question What additional information should be provided when
reporting a multi-arm randomized trial that uses a parallel-group
design but has 3 or more groups?
Findings This reporting guideline is an extension of the
Consolidated Standards of Reporting Trials (CONSORT) 2010
Statement. Ten CONSORT items have been modified, and
examples of good reporting and an accompanying explanation for
each extension item are provided.
Meaning The guideline checklist can facilitate transparent
reporting of multi-arm randomized trials and may help assist
evaluations of rigor and reproducibility, enhance understanding of
the methodology, and make results more useful for clinicians,
journal editors, reviewers, guideline authors, and funders.
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Table. Checklist for Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statementa
Section/Topic
Item
No. CONSORT 2010 Statement Checklist Item Multi-Arm Trial Extension
Title and abstract
1a Identification as a randomized trial in the title Identification as a multi-arm randomized trial in the title
or an indication of the number of treatment groups that the
participants were randomly assigned to
1b Structured summary of trial design, methods, results,
and conclusions (for specific guidance see CONSORT
for abstracts)7
Specification of the number of treatment groups; details of any
groups added or dropped
Introduction
Background and objectives 2a Scientific background and explanation of rationale Rationale for using a multi-arm design
2b Specific objectives or hypotheses Specification of the research question referring to all of the
treatment groups
Clear statement of all hypotheses to be tested and the primary
comparisons involved
Methods
Trial design 3a Description of trial design (such as parallel, factorial)
including allocation ratio
Specification of the number of treatment groups
3b Important changes to methods after trial
commencement (such as eligibility criteria), with
reasons
Details of any treatment groups added or dropped (if relevant),
with reasons, and/or changes to the allocation ratio
Participants 4a Eligibility criteria for participants
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufficient details
to allow replication, including how and when they were
actually administered
Outcomes 6a Completely defined prespecified primary and secondary
outcome measures, including how and when they were
assessed
6b Any changes to trial outcomes after the trial
commenced, with reasons
Sample size 7a How sample size was determined Planned sample size with details of how it was determined for
each primary comparison
7b When applicable, explanation of any interim analyses
and stopping guidelines
Randomization
Sequence generation 8a Method used to generate the random allocation
sequence
8b Type of randomization; details of any restriction, such
as blocking and block size
Allocation concealment
mechanism
9 Mechanism used to implement the random allocation
sequence, such as sequentially numbered containers,
describing any steps taken to conceal the sequence
until interventions were assigned
Implementation 10 Who generated the random allocation sequence, who
enrolled participants, and who assigned participants to
interventions
Blinding 11a If applicable, who was blinded after assignment to
interventions (eg, participants, care providers,
individuals assessing outcomes) and how
11b If relevant, description of the similarity of interventions
Statistical methods 12a Statistical methods used to compare groups for primary
and secondary outcomes
Explicitly state if no adjustments for multiplicity were applied;
if adjustments were applied, state the method used
12b Methods for additional analyses, such as subgroup





13a For each group, the numbers of participants who were
randomly assigned, received intended treatment, and
were analyzed for the primary outcome
13b For each group, losses and exclusions after
randomization with reasons included
Recruitment 14a Dates defining the periods of recruitment and
follow-up
If periods of recruitment and follow-up are different across
treatment groups (eg, groups were added or dropped),
the periods of recruitment and follow-up, reason(s) for the
differences, and any statistical implications should be described
14b Why the trial ended or was stopped
Baseline data 15 A table showing baseline demographic and clinical
characteristics for each group
(continued)
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reporting the abstract of a randomized trial was reviewed. No sepa-
rate checklist for abstracts is proposed, with the 1 proviso that au-
thors report all of the objectives clearly and specify the number of
treatment groups.
CONSORT Checklist Extension for Multi-Arm Trials
Title and Abstract
Item 1a. CONSORT 2010: Identification as a randomized trial
in the title.
Extension for multi-arm trials: Identification as a multi-arm random-
ized trial in the title or an indication of the number of treatment
groups that the participants were randomly assigned to.
HARMONY 3: 104-week randomized, double-blind, placebo- and
active-controlled trial assessing the efficacy and safety of albiglu-
tide compared with placebo, sitagliptin, and glimepiride in patients
with type 2 diabetes taking metformin.9
Efficacy of oral risperidone, haloperidol, or placebo for symp-
toms of delirium among patients in palliative care: a randomized
clinical trial.10
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomi-
sation Trial (MS-SMART): a multiarm phase IIb randomised, double-
blind, placebo-controlled clinical trial comparing the efficacy of three
neuroprotective drugs in secondary progressive multiple sclerosis.11
Explanation: The ability to identify a report of a randomized trial
as such in an electronic database depends largely on how the
report was indexed. Indexers may not classify a report as a ran-
domized trial if the authors do not explicit ly state this
information.12 To help ensure that a study is appropriately
indexed and easily identified, authors should use the word “ran-
domized” in the title and indicate the number of arms (treatment
groups) that the participants were randomly assigned to. This
issue applies to multi-arm trials also. Article titles normally have a
restricted word count, and listing some or all of the interventions
is cumbersome, so adding the word “multi-arm” (or multi-group)
instead would be efficient and informative.
Background and Objectives
Item 2a. CONSORT 2010: Scientific background and explanation
of rationale.
Extension for multi-arm trials: Rationale for using a multi-arm design.
Many patients do not respond to monotherapy, and combina-
tions of drugs are often recommended despite little evidence.
Lithium plus valproate is often recommended after failure of first-
line monotherapy. Should this combination have additive pharma-
cological effects and prove better than monotherapy, it could be an
appropriate first-line therapy. We report here on BALANCE (Bipolar
Affective disorder: Lithium/ANti-Convulsant Evaluation), a ran-
domized trial that was designed to establish whether lithium plus
valproate semisodium is better than monotherapy with either drug
alone for prevention of relapse in bipolar I disorder.13
Explanation: When a trial compares 2 parallel groups, it is evident
that the aim is a comparison of those groups. With 3 or more inter-
vention groups, however, the intended main comparison or com-
parisons may not be clear. Because each intervention group should
be included only if it contributes to a specific research question,
Table. Checklist for Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statementa (continued)
Section/Topic
Item
No. CONSORT 2010 Statement Checklist Item Multi-Arm Trial Extension
Numbers analyzed 16 For each group, number of participants (denominator)
included in each analysis and whether the analysis was
by original assigned groups
Outcomes and estimation 17a For each primary and secondary outcome, results for
each group, and the estimated effect size and its
precision, such as 95% CI
Results for each prespecified comparison of treatment groups
17b For binary outcomes, presentation of both absolute and
relative effect sizes is recommended
Ancillary analyses 18 Results of any other analyses performed, including
subgroup analyses and adjusted analyses,
distinguishing prespecified from exploratory
Harms 19 All important harms or unintended effects in each
group (for specific guidance,
see CONSORT for harms)8
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias,
imprecision, and, if relevant, multiplicity of analyses
Generalizability 21 Generalizability (external validity, applicability) of the
trial findings
Interpretation 22 Interpretation consistent with results, balancing
benefits and harms, and considering other
relevant evidence
Other information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed,
if available
Funding 25 Sources of funding and other support (such as supply
of drugs), role of funders
a It is strongly recommended that this checklist is read in conjunction with the CONSORT 2010 Statement Explanation and Elaboration5 for important clarification
on the items.
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it follows that each arm should contribute to at least 1 preplanned
comparison. Authors should justify the use of a multi-arm design and,
in the introduction of the article, indicate why they chose to inves-
tigate the interventions they studied and which specific compari-
sons were planned. In a situation, for example, in which 1 of the
planned interventions is a combination of 2 active interventions, au-
thors should comment on why they did not perform a factorial trial.
Typically, this “incomplete” factorial design might be used in cases
in which it would be unethical to withhold active treatment from a
group of patients.
Item 2b. CONSORT 2010: Specific objectives or hypotheses.
Extension for multi-arm trials: Specification of the research ques-
tion referring to all of the treatment groups. Clear statement of all
hypotheses to be tested and the primary comparisons involved.
Abstract (Objective): To determine efficacy of risperidone or halo-
peridol relative to placebo in relieving target symptoms of delirium
associated with distress among patients receiving palliative care.
Introduction: The aim of this study was to determine if risperi-
done or haloperidol, given in addition to managing precipitants of de-
lirium and providing individualized supportive nursing care, pro-
vides additional benefits in reducing target symptoms of delirium
associated with distress when compared with placebo. The primary
null hypothesis was that there was no difference between risperi-
done and placebo, and secondarily, no difference between haloperi-
dol and placebo.10
Explanation: Eight possible analyses emanate from a 3-arm trial,
(groups A, B, and C) of which most trials will include 2 or 3 (Box).
The number of potential comparisons proliferates rapidly as the
number of intervention groups increases; each group should
appear in at least 1 comparison. Thus, unless the intention is only
to compare all groups at once (which is not a particularly sensible
approach, except for possibly in a dose-response study) there will
be at least k−1 comparisons made in the analysis of a trial with
k treatment arms. The maximum number of 2-group/paired com-
parisons is k×(k−1)/2 (eg, for a 4-arm trial there are 6 possible
2-group comparisons).
Thus, prespecification of analyses is particularly important,
and authors should report all of the planned primary, secondary,
and exploratory comparisons. Otherwise, there is a major risk of
highlighting and being misled by an observed difference without
considering the large number of possible analyses. In all cases, and
especially when many comparisons are planned, it is helpful to indi-
cate the primary comparison(s). These comparisons should also be
described in the explanation of the planned sample size (item 7a).
The planned comparisons may not be considered equally impor-
tant. For example, one 2-group comparison may be the primary
focus of the trial. This distinction is relevant when considering
whether to make an adjustment for multiple comparisons. Alterna-
tively, a hierarchical approach to hypothesis testing could prevent
any issues with multiple comparisons (item 12a). Some multi-arm
trials combine a test of superiority with a test of noninferiority. For
example, Foa et al examined whether 10 sessions of prolonged
exposure therapy (a trauma-focused cognitive behavioral therapy)
delivered over 2 weeks (massed therapy) was more effective than
minimal contact (control) and noninferior to 10 sessions of pro-
longed exposure therapy delivered over 8 weeks (spaced therapy)
for reducing symptom severity among active duty military person-
nel with posttraumatic stress disorder.16
Methods
Item 3a. CONSORT 2010: Description of trial design
(such as parallel, factorial) including allocation ratio.
Extension for multi-arm trials: Specification of the number of treat-
ment groups.
In this pragmatic, open-label randomised trial, patients newly
diagnosed with Parkinson's disease were randomly assigned (by
telephone call to a central office; 1:1:1) between levodopa-sparing
therapy (dopamine agonists or MAOBI [monoamine oxidase type B
inhibitors]) and levodopa alone.17
This was a phase 3, randomized, double-blind, placebo- and
active-controlled parallel-group study that occurred between
17 February 2009 and 21 March 2013. Eligible patients were
stratified by HbA1c level (<8.0% [<63.9 mmol/mol] vs. 8.0%
[63.9 mmol/mol]), history of myocardial infarction (MI), and age
(<65 vs. 65 years) and were randomly assigned (3:3:3:1) to
receive, in addition to their background metformin, 1 of 4 treat-
ments at baseline: albiglutide 30 mg, sitagliptin 100 mg, glimep-
iride 2 mg, or placebo. Matching placebos for albiglutide, sita-
gliptin, and glimepiride were used to maintain blinding to
treatment.9 [An improvement on the reporting would be to explain
why a 3:3:3:1 allocation was used.]
Explanation: In terms of readability and understanding the design
and rationale of a multi-arm trial, specification of the number of treat-
ment groups is essential. Describing the allocation ratio offers in-
sight and clarity, especially if an unequal allocation ratio is chosen,
in which case an explanation is necessary.
Illustrating the structure and participant flow in a multi-arm trial
will usually provide insight to the reader. An example demonstrat-
ing a trial structure and participant flow is shown in the eFigure in
the Supplement.9 Nevertheless, the presentation of the trial struc-
ture and participant flow in this example could be improved in terms
of the labeling (eg, position of “Follow-up” in diagram A), the ab-
sence of 2 arrows leading from the randomization box, and the de-
scription of the information provided (eg, what is meant by “Termi-
nated by sponsor” in diagram B?).
Item 3b. CONSORT 2010: Important changes to methods after trial
commencement (such as eligibility criteria), with reasons.
Extension for multi-arm trials: Details of any treatment groups added
or dropped (if relevant) with reasons and/or changes to the alloca-
tion ratio.
Example (in which an arm was dropped).
The original study was a multicentre, blinded, randomized,
parallel-group trial in which patients were assigned to receive ris-
peridone (Risperdal, Eisai), donepezil, or placebo for 12 weeks,
after 4 weeks of psychosocial treatment. The target sample size
was 285 people with Alzheimer’s disease. Recruitment started in
November 2003 but was suspended in March 2004, following the
recommendation by the United Kingdom Committee for Safety of
Medicines that risperidone and olanzapine not be used for the
treatment of behavioral symptoms in dementia. The trial was
restarted in July 2004 with a two-group design (donepezil and pla-
cebo), and recruitment ended in September 2005.18
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Box. Methodological Issues in Multi-Arm Randomized Trials
Design
Research Objectives
Trials with more than 2 treatment arms will generally either address a more
complex question than a 2-arm trial or, more commonly, will attempt to
addressresearchquestionsaboutmorethan1intervention.Authorsshould
explicitly define the objectives of a multi-arm trial, referring to all the
arms of the study and prespecifying all planned comparisons of
intervention groups to partly mitigate the effects of multiplicity and
accusations of data dredging (ie, unplanned exploratory analyses).
Eligibility Criteria
In trials that involve multiple drugs, safety/toxicity profiles may
reduce the pool of potential participants, adversely affecting
recruitment and generalizability.
Patient and/or recruiting center characteristics or lack of equipoise
or resources may preclude randomization to 1 of the groups.
A multi-arm trial could include 2 research treatments with
contraindications but allow patients to be randomized to other arms.
For example, everyone might not be suitable for a type of surgical
procedure but may be able to contribute to an evaluation of a drug,
so patients could be randomized as control vs surgery vs drug,
control vs surgery (if not suitable for drug therapy), or control
vs drug (if not suitable for surgery).
Sample Size
The sample size for a multi-arm phase 3 trial should depend upon the
plannedprimarycomparison(s).Thesamplesizepergroupshouldbelarge
enough that prespecified primary comparisons have adequate power.
Use of Placebos for Blinding
Inthemulti-armdesign,blindingneedstoensurethatnoneofthearmscan
be identified. If route of administration of 2 experimental drugs varies
(eg, oral vs intravenous), blinding can become invasive, expensive,
and an additional burden on participants. As the number of experimental
drug arms increases, blinding may become more problematic.
3-Arm Trial: Placebo and Active Control
Three-arm trials that include an active control group as well as a
placebo group can establish whether a failure to distinguish a test
treatment effect from placebo implies ineffectiveness of the new
test treatment or is simply the result of a trial that lacked the ability
to identify an active drug. The comparison of placebo to the active
control (standard drug) in such a design provides internal evidence
of assay sensitivity (a property of a clinical trial defined as the ability
of a trial to distinguish an effective treatment from a less effective or
ineffective intervention). An unequal allocation ratio could be used
to make the active groups larger than the placebo group to improve
the precision of the active drug comparison. This allocation ratio may
increase acceptability to participants and investigators because
there is a lower probability of being allocated to placebo.14
Conduct
Interim Analysis and Stopping Guidelines
Many trials employ formal methods for interim monitoring and early
stopping guidelines. These guidelines prompt consideration for
recruitment to stop early for strong evidence of benefit or harm or,
alternatively, futility. Multiple treatment arms add to the complexity
of interpreting interim analyses in the context of early stopping
guidelines. Depending on the type/structure of a multi-arm trial, an
ethical dilemma may arise as a result of an interim analysis, such as if
sufficiently strong evidence of a benefit of one of the treatment
interventions vs the control is observed. If this intervention is
considered a significant improvement over the control arm,
recruitment into the control arm may have to be stopped, which
may result in recruitment to the other treatment intervention arms
stopping because of a lack of a concurrent control group. Because
the trial may be stopped if any of the treatment intervention-control
comparisons cross an efficacy early stopping boundary, multiplicity
adjustment is required for the efficacy boundaries.
Analysis
Analysis Strategy
If the main objective is to examine whether the interventions differ,
but not how they differ, it would be appropriate to compare all
groups at once using a single global test of significance. If the main
objective is to examine a trend, a dose-response model should be
used. More often, 2 or more specific comparisons are made between
particular pairs or combinations of treatments. However, the
number of possible comparisons can be considerable.
Multiple Treatments Comparisons
For a 3-arm trial (eg, treatments A, B, and C) there are several
possible comparisons, including:
1. Comparing all 3 groups at once (A vs B vs C); a global test of
unordered groups or a test for trend across ordered groups.
2. Comparing 1 group to the other 2 groups combined (A plus B vs C)
and then the groups that were combined to each other (A vs B);
A and B might be low and high doses of the same drug and the first
comparison could be of treated vs untreated, followed by a
comparison of the 2 treated groups, or A and B might be 2
antibiotics in the same class vs C as a member of a different class
(note: the labeling in this example is arbitrary).
3. All pairwise comparisons: A vs B, A vs C, and B vs C.
4. Comparing A vs C and B vs C, but not A vs B; for example,
comparing 2 treatments, separately, to the control but not
comparing the 2 treatments to each other.
Reporting and Interpretation
Multi-armtrialsoftenaddresscomplexandintricatequestionsconcurrently
and, as such, have a different focus than 2-arm trials. For example,
following a prespecified comparison of all groups, the interpretation of a
statistically significant global test is not straightforward. The investigators
have evidence to reject the hypothesis that all the interventions were
equally effective, but no clear indication of precisely where the differences
lie. It is tempting, but incorrect, simply to use the observed data to draw
more precise conclusions. It is incorrect, for example, to deduce that the
intervention with the most favorable results is better than the others,
because this question has not been examined explicitly.
Moreover, multiple pairwise comparisons may yield seemingly
paradoxical results. For example, in a trial of 2 active interventions (A and
B) vs placebo, it is possible to find that A is significantly better than the
placebobutthatBisnotsignificantlydifferentfromeitherAortheplacebo.
It is also possible that no pairwise comparison is significant despite a
significant global test. These problems are well known in agricultural
research and other research areas in which formal multi-arm comparisons
arecommon,butthereis littleexperienceofsuchissuesinclinicalresearch.
Interpretation issues relating to the multiplicity of comparisons are
of general relevance. Clinicians frequently find that the addition of a
group to a trial enhances rather than diminishes the information
gained.15 In many such trials, interpretation of results adjusted for
multiplicity frequently causes rather than solves interpretational
problems. Yet, sometimes a particular analysis dictates adjustment
for multiple comparisons; if those adjustments are indeed
unsophisticated and liable to overcorrection, the authors should
account for that in their interpretation.
Readers of a report of a multi-arm trial will expect a description of
how the primary and secondary comparisons were handled,
emanating from the multiple intervention groups. Most authors and
readers are likely to bear in mind the number of analyses performed
regardless of whether any formal adjustment is made.
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Example (in which an arm was added).
A total of 1493 patients with schizophrenia were recruited at 57
U.S. sites and randomly assigned to receive olanzapine (7.5 to 30 mg
per day), perphenazine (8 to 32 mg per day), quetiapine (200 to
800 mg per day), or risperidone (1.5 to 6.0 mg per day) for up
to 18 months. Ziprasidone (40 to 160 mg per day) was included after
its approval by the Food and Drug Administration. The primary aim
was to delineate differences in the overall effectiveness of these
five treatments.19
Explanation: If treatment arms are added or dropped, the number
of participants available for an unbiased and valid comparison is af-
fected (ie, only participants randomized concurrently should be com-
pared). In the example above in which a treatment arm was discon-
tinued, the allocation ratio went from 1:1:1 to 1:1 (evident from the
participant flow diagram and results tables), so the probability of re-
ceiving one of the interventions changed from 0.33 to 0.50, but ran-
domization continued with roughly equal probability of receiving
either intervention. In the example of adding an arm, the allocation
ratio was not explicitly ever mentioned.
This item relates to a conventional multi-arm trial and not to
an adaptive design in which arms may be dropped using prespeci-
fied rules. Such designs offer greater efficiency while minimizing
the number of participants that need to be randomized. Report-
ing guidelines for adaptive trials will be covered by the Adaptive
Designs CONSORT Extension.20
Item 7a. CONSORT 2010: How sample size was determined.
Extension for multi-arm trials: Planned sample size with details of
how it was determined for each primary comparison.
Sample size calculations were based on the assumption that
34% of placebo-treated patients and 54-64% of tadalafil-treated
patients (once daily and on demand) would achieve an IIEF-EF
score [International Index of Erectile Function-Erectile Function]
after DFW [drug-free washout]. A sample size of 412 randomised
patients provided 84% power to detect a 20% difference in pro-
portions in the two pairwise comparisons of tadalafil (once daily
and on demand) versus placebo (20% drop-out rate assumed).21
Because a high degree of benefit would be needed to change
routine clinical practice, we specified a 3.3% absolute reduction on
the basis of estimated incidence in the control group of 11% (30%
relative reduction; odds ratio [OR] 0.67). With 90% power and
2.5% significance level to account for the two comparisons, and
allowing for an attrition rate of 15%, we needed to recruit 2,345
participants in each group (7,035 participants overall). Two com-
parisons of equal importance were tested in the trial: silver alloy
catheters versus PTFE [polytetrafluoroethylene] catheters and
nitrofural catheters versus PTFE catheters.22
Explanation: The sample size for a multi-arm trial should corre-
spond to the planned primary comparisons (item 2b). The ap-
proach to sample size is determined by the structure of the inter-
ventions being compared and the nature of the planned analyses
(Box). When pairwise comparisons are planned, the sample size will
usually be determined to give adequate power to evaluate each of
the intended primary comparisons. If investigators deem that they
need to adjust for multiple comparisons, the planned sample size
may be inflated to account for that adjustment (item 7a).
Item 12a. CONSORT 2010: Statistical methods used to compare
groups for primary and secondary outcomes.
Extension for multi-arm trials: Explicitly state if no adjustments for
multiplicity were applied; if adjustments were made, state the
method used.
Examples (in which adjustments were not made).
The hypotheses were that the high-rate group, the delayed-
therapy group, or both would have a reduced risk of a first occur-
rence of inappropriate therapy, as compared with the conventional-
therapy group. The two trials were conducted in parallel, with
inference made in each, and no adjustment for multiple compari-
sons was deemed appropriate.23
All P values are two-sided with no adjustment made for mul-
tiple comparisons.24
Examples (in which adjustments were made).
We assessed urinary tract infection outcomes with logistic re-
gression and summarised findings as absolute percentage risk dif-
ferences and ORs, both with 95% CIs calculated as 97·5% confi-
dence intervals to adjust for the two comparisons. For the primary
analysis, p=0·025 was regarded as significant.22
For both [Visual Analogue Scale] VAS-immediate pain ratings
and pressure data, if the Shapiro-Wilk normality test was passed,
repeated measures one-way ANOVA [Analysis of variance] with
Bonferroni correction post-hoc pairwise comparisons was con-
ducted to explore any significant difference (P<0.05) between the
test conditions.25
… we calculated that we would need to enroll 810 patients in each
group for the study to have 90% power to show the superiority of
apixaban over placebo, at a two-sided alpha level of 0.05, with the
use of the Hochberg multiple-testing method.26
Explanation: In general, multi-arm trial analysis strategies may
have 2 broad objectives. First, investigators examine variation in
efficacy of several interventions, which can be addressed by an
overall analysis comparing all groups at once. Such an analysis is
unlikely to be fully satisfactory because it will not indicate the
areas of differences. Second, 2 or more specific pairwise compari-
sons can be made between particular treatments, as described
above. In a particular trial, both types of analyses may be per-
formed. One strategy (commonly recommended in agricultural
analyses and other experiments) is to first perform a global statis-
tical test across all groups, and only to proceed to paired compari-
sons if the global test is statistically significant. This strategy does
not seem especially desirable for the analysis of clinical trials,
which require a more focused approach to the evaluation of treat-
ment comparisons.
Two further complications may be present. First, 2 (or more)
of the treatments may be different doses or durations of the
same drug or intervention. In such cases, it may be of most inter-
est to examine whether there is a dose-response relation rather
than simply testing the significance of differences between pairs
of treatments. Second, 2 of the groups may receive variants of
the same basic intervention. For example, they may receive the
same drug either orally or intravenously. Investigators might first
compare these groups combined vs the comparison group (usu-
ally placebo or standard treatment) before considering whether
the 2 variants might differ. Groups receiving different doses may
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also sometimes be considered in this way. When such an analysis
is planned, researchers may sometimes consider that the groups
should be allocated in a 1:1:2 ratio to maximize the power of the
first comparison. Statistical adjustment for multiple comparisons
invokes debate among methodologists, and there is no consen-
sus. While some would use such an adjustment, others would
never apply adjustments.27,28Investigators may avoid multiplicity
problems with analytical approaches. Some examples include:
• Using a single global test of significance across comparison groups
(eg, comparing A vs B vs C in a 3-arm trial) and avoiding multiple
comparisons. Of note, a single global test across all the treat-
ments is of limited use.29
• Modeling a dose-response relationship and eliminating mul-
tiple comparisons.30
• Using a prioritized sequence of tests. For example, investigators
might decide upon the new 300-mg antibiotic vs standard treat-
ment as the priority test and, if that comparison is statistically sig-
nificant, continue to the 200-mg antibiotic vs standard treat-
ment comparison. A prioritized sequence of tests addresses
multiplicity without adjustments.31
• Not making adjustments for multiplicity while transparently
reporting all comparisons made. Many multi-arm trials are
designed for direct comparison of unrelated treatments with a
control arm, such as comparing A vs C and B vs C in a 3-arm trial.
Adjustments for multiple comparisons generally need not play
a role in such multi-arm trials.2,15,32,33
Sometimes formal adjustments for multiplicity are unavoid-
able; some regulators, such as the European Medicines Agency,
require such adjustments. As stated in the European Medicines
Agency’s guideline on multiplicity issues in clinical trials, “as a gen-
eral rule it can be stated that control of the study-wise type I error
is a minimal prerequisite for confirmatory claims.”34 However,
even when adjustment becomes appropriate, implementation
becomes problematic. Bonferroni adjustments are often recom-
mended, usually because of their simplicity. However, other
adjustment strategies sometimes perform better on the overall
control of the type-1 error rate (usually called the family-wise
type-1-error [FWER]),32,35-37 while performing worse on the prob-
ability of more than 1 false positive.32 The adjustments frequently
provide overcorrection for multiplicity, especially the Bonferroni
adjustment. This approach becomes overly conservative as
the correlation among the comparisons becomes higher. Other
approaches, including the Holm, Hochberg, Dunnett test,
and adjusted Hochberg mehod, have been compared to the
Bonferroni approach.32 All methods appear less conservative
than the Bonferroni.
Results
Item 14a. CONSORT 2010: Dates defining the periods of recruitment
and follow-up.
Extension for multi-arm trials: If periods of recruitment and
follow-up are different across treatment groups (eg, groups were
added or dropped), the periods of recruitment and follow-up, rea-
son(s) for the differences, and any statistical implications should
be described.
Methods (Study Setting and Design): The study was con-
ducted between January 2001 and December 2004 at 57 clinical
sites in the United States (16 university clinics, 10 state mental
health agencies, 7 Veterans Affairs medical centers, 6 private non-
profit agencies, 4 private-practice sites, and 14 mixed-system
sites). Patients were initially randomly assigned to receive olanza-
pine, perphenazine, quetiapine, or risperidone under double-blind
conditions and followed for up to 18 months or until treatment was
discontinued for any reason (phase 1). (Ziprasidone was approved
for use by the Food and Drug Administration [FDA] after the study
began and was added to the study in January 2002 in the form of
an identical-appearing capsule containing 40 mg).
Methods (Statistical Analysis): … Ziprasidone was added to
the trial after approximately 40 percent of the patients had been
enrolled… and comparisons involving the ziprasidone group were
limited to the cohort of patients who underwent randomization
after ziprasidone was added (the ziprasidone cohort). In general,
the trial had a statistical power of 85 percent to identify an abso-
lute difference of 12 percent in the rates of discontinuation
between two atypical agents; however, it had a statistical power…
of 58 percent for comparisons involving ziprasidone… The overall
difference among the olanzapine, quetiapine, risperidone, and per-
phenazine groups was evaluated with the use of a test with
3 degrees of freedom (df). If the difference was significant at
a P value of less than 0.05, the three atypical-drug groups were
compared with each other by means of step-down or closed testing,
with a P value of less than 0.05 considered to indicate statistical sig-
nificance… The ziprasidone group was directly compared with the
other three atypical-drug groups and the perphenazine group within
the ziprasidone cohort by means of a Hochberg adjustment for four
pairwise comparisons. The smallest resulting P value was compared
with a value of 0.013 (0.05÷4). [reiterated in a footnote to Table 2
and Figure 2 legend relating to Outcome Measures of Effectiveness
in the Intention-To-Treat (ITT) population]
Results (Discontinuation of Treatment): … Within the cohort of
889 patients who underwent randomization after ziprasidone was
added to the trial, those receiving olanzapine had a longer interval
before discontinuing treatment for any cause than did those in the
ziprasidone group (hazard ratio, 0.76; P=0.028). However, this dif-
ference was not significant after adjustment for multiple compari-
sons (required P value, 0.013).19
Explanation: Incorporating an emerging therapy as a new random-
ization group in a clinical trial that is open to recruitment would be
desirable to researchers, regulators, and patients to ensure that the
trial remains current, new treatments are evaluated as quickly as
possible, and the time and cost for determining optimal therapies is
minimized.38 Numerous methodological and statistical implications
should be considered. These implications include (1) family-wise
error rate control due to stage effects and multiplicity, (2) that only
concurrent control group data are used for an unbiased compari-
son with the added arm(s),39 (3) statistical power (comparison with
concurrent control group data will require adequate power),
(4) the allocation ratio and/or length of recruitment into each group
(improved efficiency could be realized by adjusting the total number
of participants required and time spent recruiting to answer the pri-
mary hypotheses), (5) potential changes to the control group
(it is possible that the existing control group may be shown to be in-
ferior and, therefore, it is theoretically possible that the control group
may have to be changed), and (6) logistical considerations (eg, extra
funding, the time taken for all necessary approvals/amendments,
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sourcing drug, updating trial randomization and clinical database sys-
tems, possible effect on blinding, trial oversight, recruitment).38 The
extent to which these implications need to be considered depends
upon the nature and structure of the trial. There is potential for over-
lap with the CONSORT extension for adaptive designs.20
If recruitment into more than 1 treatment group in a multi-arm
trial is stopped prematurely, it is important to include the reasons
why, because those reasons may differ. In addition, regarding
standard CONSORT item 15 (ie, a table showing baseline demo-
graphic and clinical characteristics for each group), in a situation in
which recruitment to all treatment groups is not contemporane-
ous, a single table or multiple baseline tables could be used.
Authors must clearly state which participants are included in which
comparisons for each group.
Item 17a. CONSORT 2010: For each primary and secondary
outcome, results for each group, and the estimated effect size
and its precision (such as 95% confidence interval).
Extension for multi-arm trials: Results for each prespecified com-
parison of treatment groups.
Primary Outcomes – At 6 months, the AVVQ [Aberdeen Vari-
cose Veins Questionnaire] score in the foam group was signifi-
cantly higher (indicating a worse disease-specific quality of life)
than that in the surgery group, but the difference was moderate
(effect size, −1.74; 95% confidence interval [CI], −2.97 to −0.50;
P=0.006). The improvement in the AVVQ score in the laser group
did not differ significantly from that in the surgery group. There
were no significant differences between the groups in the EQ-5D
score [a standardized instrument for measuring generic health sta-
tus] or the SF-36 [Short Form Health Survey] physical component
score. For the post hoc analysis of treatment with laser versus
foam, the only significant difference was in the SF-36 mental com-
ponent score, which was slightly higher (better generic quality of
life) in the laser group than in the foam group (effect size, 1.54;
95% CI, 0.01 to 3.06; P=0.048)… Secondary Outcomes – Quality of
Life. At 6 weeks, significant between-group differences (P<0.005)
included a lower AVVQ score (indicating a better disease-specific
quality of life) in the surgery group than in the foam group (effect
size, −2.3; 95% CI, −3.7 to −0.9) and lower SF-36 scores (indicating
a worse generic quality of life) in the surgery group than in the
laser group for the domains of bodily pain (effect size, −2.7; 95% CI,
−4.4 to −0.9), vitality (effect size, −2.3; 95% CI, −3.9 to −0.8), role
limitations due to emotional health (effect size, −2.4; 95% CI, −4.0
to −0.8), and role limitations due to physical health (effect size,
−3.5; 95% CI, −5.2 to −1.8). These four SF-36 domain scores did not
differ significantly (with P<0.005 considered to indicate statistical
significance) between groups at 6 months. For the post hoc com-
parisons of laser treatment vs foam treatment, only the EQ-5D
score was significantly lower (indicating a worse generic quality
of life) in the foam group at 6 weeks (0.044; 95% CI, 0.014
to 0.074).40
Explanation: Investigators should plan the comparisons intended,
document them in the protocol and statistical analysis plan, and re-
port them all in the trial report with appropriate interpretations. If
intervention groups have been added or dropped during the trial,
it is important that the analysis addresses the implications of doing
so. If investigators employed measures to control the overall sig-
nificance level (eg, if they conducted a single global test of signifi-
cance across comparison groups, modeled a dose-response rela-
tionship, or used a prioritized sequence of tests), those details should
be reported. If investigators conducted an analysis that dictated for-
mal adjustments for multiplicity, those methods and limitations
should be reported. As discussed previously (item 12a), many multi-
arm trials will not employ formal adjustments for multiplicity. In those
cases, investigators should still transparently report all compari-
sons undertaken, planned and unplanned, and provide appropri-
ate interpretations of the results.
Discussion
Item 20. CONSORT 2010: Trial limitations, addressing sources of
potential bias, imprecision, and, if relevant, multiplicity of analyses.
While no specific extension to the standard CONSORT item is rec-
ommended here, authors should address the strengths and limita-
tions of multi-arm trials with regard to issues detailed in the Box.
Discussion
Multi-arm trials require careful thought and planning. They offer the
opportunity to address more than 1 research question, may accel-
erate the evaluation of new interventions, and can facilitate head-
to-head comparisons with competing treatment options, poten-
tially resulting in patient benefit while optimizing the use of
resources. Multi-arm trials may be more appealing than trials with
only 2 arms to participants and clinicians because typically there is
an increased probability of receiving an experimental intervention
rather than standard care. However, investigators should always be
mindful that the efficiency advantages of multi-arm trials and the
opportunity to evaluate more interventions in a shorter time are con-
tingent upon recruiting and collating outcomes on the requisite num-
ber of participants.
Multi-arm randomized trials are common, and it is important that
reports of these trials include information on features specific to the
design to allow readers to make an accurate assessment of the con-
duct of the trial and interpretation of the results. Transparent and
complete reporting is an essential prerequisite for reproducibility.
Good reporting also facilitates the identification and inclusion of
multi-arm trials in systematic reviews. However, multi-arm trials, es-
pecially trials with more than 3 treatment arms, are challenging to
design and analyze.
This Special Communication provides a proposed extension to
the widely adopted CONSORT 2010 Statement to enable the full and
accurate reporting of multi-arm randomized trials. Such trials re-
quire clear objectives and hypotheses referring to all of the treat-
ment arms and identification of the primary comparisons being
made. The sample size should be prespecified and the issue of ad-
justment for multiple testing should at least be acknowledged. If pe-
riods of recruitment and follow-up are different across treatment
groups (eg, groups were added or dropped), the periods and rea-
sons for differences should be reported, and any statistical implica-
tions should be addressed.
Multiplicity adjustment for multiple comparisons among
groups in a multi-arm randomized trial remains a challenging
issue. Many multi-arm trials are conducted for efficiency reasons.
They compare distinct treatments/interventions against a single
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control group, which could easily have been done in multiple
separate trials rather than a single multi-arm trial. For a multi-arm
trial design in which several experimental interventions share a
control arm, the trial is focused on evaluating the research ques-
tion for each intervention separately. The interpretation of the
results of one comparison ordinarily has no direct bearing on the
interpretation of the others. Many trialists/methodologists argue
that multiplicity adjustments are not necessary in such instances
because such adjustments would not be necessary if the inter-
ventions were compared in separate trials.2,15,32,33,41,42 Some
multi-arm trials evaluate several different doses of the same
agent against a control group, which represents related compari-
sons. In such situations, trialists and methodologists tend to rec-
ommend multiplicity adjustments.2,32,33,37 An example of this
situation occurs with certain decision-making criteria in submis-
sions to a regulatory agency for drug approval. If the sponsor
specifies more than 1 treatment comparison and proposes to
claim a treatment effect if 1 or more of the doses are statistically
significant, most trialists and methodologists suggest an adjust-
ment for multiplicity.2,15,32,33,41,42 But sweeping declarations of
always or never needing to adjust for multiple testing should be
ignored; the decision regarding adjustment depends on the
objectives, design, and analysis.
Some multi-arm trials may also have other special features,
such as being crossover, cluster, or factorial trials. For such trials,
the specific recommendations for all such types of trial will be rel-
evant. Use of the CONSORT Statement for the reporting of
2-group parallel trials has been shown to be associated with
improved quality of reporting.43 The routine use of this proposed
extension to the CONSORT Statement is intended to promote
similar improvements.
The CONSORT Group will continue to monitor and revise its
recommendations and is developing checklists and flow diagrams
to help improve the quality of reporting of clinical trials of various
designs. Other similar extensions and updates are in preparation,
and the most up-to-date versions of all CONSORT recommenda-
tions can be found on the CONSORT website (http://www.
consort-statement.org).
Conclusions
This extension of the CONSORT 2010 Statement provides specific
guidance for the reporting of multi-arm parallel-group randomized
clinical trials and should help to provide greater transparency and
accuracy in the reporting of these types of clinical trials.
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